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Abstract
Background: Studying cytokine/chemokine responses in severe influenza infections caused by different virus subtypes may
improve understanding on pathogenesis.
Methods: Adults hospitalized for laboratory-confirmed seasonal and pandemic 2009 A/H1N1 (pH1N1) influenza were
studied. Plasma concentrations of 13 cytokines/chemokines were measured at presentation and then serially, using
cytometric-bead-array with flow-cytometry and ELISA. PBMCs from influenza patients were studied for cytokine/chemokine
expression using ex-vivo culture (Whole Blood Assay,6PHA/LPS stimulation). Clinical variables were prospectively recorded
and analyzed.
Results: 63 pH1N1 and 53 seasonal influenza patients were studied. pH1N1 patients were younger (mean6S.D. 42.8619.2
vs 70.5616.7 years), and fewer had comorbidities. Respiratory/cardiovascular complications were common in both groups
(71.4% vs 81.1%), although severe pneumonia with hypoxemia (54.0% vs 28.3%) and ICU admissions (25.4% vs 1.9%) were
more frequent with pH1N1. Hyperactivation of the proinflammatory cytokines IL-6, CXCL8/IL-8, CCL2/MCP-1 and sTNFR-1
was found in pH1N1 pneumonia (2–15 times normal) and in complicated seasonal influenza, but not in milder pH1N1
infections. The adaptive-immunity (Th1/Th17)-related CXCL10/IP-10, CXCL9/MIG and IL-17A however, were markedly
suppressed in severe pH1N1 pneumonia (2–27 times lower than seasonal influenza; P2values,0.01). This pattern was
further confirmed with serial measurements. Hypercytokinemia tended to be sustained in pH1N1 pneumonia, associated
with a slower viral clearance [PCR-negativity: day 3–4, 55% vs 85%; day 6–7, 67% vs 100%]. Elevated proinflammatory
cytokines, particularly IL-6, predicted ICU admission (adjusted OR 12.6, 95%CI 2.6–61.5, per log10unit increase; P=0.002), and
correlated with fever, tachypnoea, deoxygenation, and length-of-stay (Spearman’s rho, P-values,0.01) in influenza
infections. PBMCs in seasonal influenza patients were activated and expressed cytokines ex vivo (e.g. IL-6, CXCL8/IL-8, CCL2/
MCP-1, CXCL10/IP-10, CXCL9/MIG); their ‘responsiveness’ to stimuli was shown to change dynamically during the illness
course.
Conclusions: A hyperactivated proinflammatory, but suppressed adaptive-immunity (Th1/Th17)-related cytokine response
pattern was found in severe pH1N1 pneumonia, different from seasonal influenza. Cytokine/immune-dysregulation may be
important in its pathogenesis.
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Introduction
Seasonal influenza affects 5–10% of the world’s population
annually, causing 3–5 million severe infections and 250,000–
500,000 deaths [1]. Typically, severe progressive influenza diseases
occur in patients who are of advanced age and have pre-existing,
immunocompromising conditions. In early 2009, a novel influenza
A/H1N1 virus (pH1N1) emerged and rapidly caused a pandemic
[1,2,3,4]. It has been estimated that in some populations, up to
20–40% of individuals were affected, and had resulted in excessive
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26050hospitalizations and deaths [1,2,4]. In the United States, 195,000–
403,000 persons were hospitalized for severe pH1N1 infection,
and 8,870–18,300 died by April 2010 [1,2,4,5]. The pH1N1 virus
has continued to co-circulate with the seasonal influenza viruses in
the community [1,3]. While most patients develop mild upper
respiratory-tract infection with pH1N1, some may progress to
develop severe lower respiratory-tract complications such as
pneumonia [1,2,4,5,6]. In contrast to seasonal influenza, young
adults and previously healthy individuals may also develop severe
diseases [2,4,5,6]. Among hospitalized adults, about 9–34% may
require intensive care because of progressive respiratory failure,
which can be associated with high mortality (14–46%); notably,
some of the manifestations (e.g. ARDS, hemophagocytosis) are
quite similar to those of H5N1 influenza [2,4,5,6,7,8,9].
Despite its burden, the pathogenesis of severe influenza disease
remains poorly understood and the management approach
uncertain. In particular, progressive pneumonitis caused by
pH1N1 is somewhat difficult to explain since the virus is neither
shown to have markedly increased virulence over seasonal
influenza viruses, nor it is a particularly strong cytokine inducer
in vitro [2,4,10,11,12,13]. Earlier reports indicated the presence of
an exuberant inflammatory cytokine response in severe pH1N1
pneumonia [8,9,10,11,13]; however how these responses com-
pared with seasonal influenza is unknown. In this study, we
examined the cytokine response patterns in adults hospitalized for
severe infections caused by pH1N1 and seasonal influenza viruses.
Their relations to disease severity and outcomes were studied.
Such information may provide important insights into the
immunopathogenic mechanisms of severe influenza disease, which
may lead to improved patient management in future.
Methods
Patients and sampling
We prospectively studied adults aged $17 years who were
hospitalized for laboratory-confirmed influenza infection during
year 2008 (two seasonal peaks)[3,7] and 2009 (first wave of pH1N1
influenza)[3,8]. Hospital admission procedures for both seasonal
and pH1N1 influenza patients have been described [7,8]. In brief,
patients presenting with acute febrile respiratory illnesses would be
considered for hospitalization if they had developed potentially
serious medical conditions/complications, exacerbation of under-
lying illnesses, or severe constitutional and respiratory symptoms
that were unmanageable at home. In all hospitalized patients,
nasopharyngeal-aspirates were collected to test for influenza virus,
regardless of perceived etiology. For seasonal influenza, the
diagnosis was established by immunofluorescence assay [7]; for
pH1N1 influenza, the diagnosis was established by a specific RT-
PCR assay [8]; virus isolation was performed in parallel in all cases
for confirmation (see below). Once diagnosed (seasonal influenza A
or B, or pH1N1), patients were identified and enrolled by the
research team on a daily basis [7,8].
After obtaining informed written consent, peripheral venous
blood samples were taken immediately at the time of recruitment
(before antiviral therapy, if given), and then twice during the
period of hospitalization until the end of first week or discharge.
Blood samples were subjected to cytokine/chemokine assays,
inflammatory-marker assays, and ex vivo PBMC cytokine/chemo-
kine production studies (see below). Nasal/pharyngeal swabs were
also taken for influenza viral RNA detection at the same time
points. Clinical information and outcomes were recorded
systemically, using a standardized research tool identical for both
the seasonal and pH1N1 influenza cohorts [7]. Ethical approval
for study was obtained from the Institutional Review Boards of the
Chinese University of Hong Kong and the Hospital Authority of
Hong Kong.
Virological investigations
All nasopharyngeal-aspirates collected at presentation were
subjected to an immunofluorescence assay for influenza A and B,
RSV and parainfluenza viruses detection as described Directi-
gen
TM Flu A+[7,8,14,15]. In 2009, a real-time RT-PCR assay
specific for the haemagglutinin gene of the pH1N1 virus was
additionally performed for diagnosis, using established method [8].
In all cases, virus isolation was performed in parallel using Madin-
Darby canine kidney cells. Subsequent subtyping of virus isolates
(seasonal H1N1, H3N2; pH1N1) was performed by the National
Influenza Centre at the Centre for Health Protection in Hong
Kong [3,7,8]. Viral RNA detection in the serially collected nasal/
pharyngeal swabs was performed using real-time RT-PCR assays
(which targeted the M-gene of influenza viruses) as previously
described [8,14,15].
Assays of plasma concentrations of cytokines/
chemokines and inflammatory-markers
EDTA blood samples were immersed in ice and transported
immediately to a biosafety level-II laboratory for processing.
Plasma was separated by centrifugation (2000 g for 10 min) at 4uC
and stored in 300 mL aliquots at 270uC until analysis. Plasma
concentrations of 10 cytokines/chemokines including interleuki-
n(IL)-1b, IL-6, IL-10, IL-12p70, tumour necrosis factor(TNF)-a,
CXCL8/IL-8, CXCL9/MIG (monokine induced by interferon-c),
CXCL10/IP-10 (interferon gamma-induced protein-10), CCL2/
MCP-1 (monocyte chemoattractant protein-1), and CCL5/
RANTES, were assayed using cytometric bead array (CBA)
reagents (BD Pharmingen, San Diego,CA) with four-color
FACSCalibur flow-cytometer (BD Biosciences Corp, San Jose,CA)
as previously described [8,15]. In CBA, different bead populations
with distinct fluorescence intensities had been coated with
capturing antibodies specific for different cytokines/chemokines.
After incubation with 50 mL plasma, the cytokine/chemokine
captured beads were mixed with phycoerythrin-conjugated
detection antibodies to form sandwich immune-complexes.
Fluorescence flow-cytometry of the beads provides simultaneous
quantification of a panel of cytokines/chemokines. In addition,
plasma concentrations of interferon(IFN)-c, sTNFR1 (soluble
tumour necrosis factor receptor 1, which indirectly indicates
TNF-a release) and interleukin(IL)-17A were quantified by ELISA
(R&D Systems Inc., MN,USA)[8,15]. These cytokines/chemo-
kines were selected for study based on our previous research and
recent literature findings [2,8,9,10,11,13]. The cytokine/chemo-
kine assays used were identical for both seasonal and pH1N1
influenza cohorts. Normal plasma reference ranges of cytokines/
chemokines (listed in Table 1) were established from .100
healthy adults [15].
Inflammatory-markers (‘acute-phase reactants’) and cortisol
levels were also studied. Serum amyloid A and cortisol were
quantified by ELISA (Antigenix America Inc, NY,USA and
ENZO Life Sciences Int’l, PA,USA). Plasma C-reactive protein
was measured using enzymatic colorimetric assay (Roche-Hitachi
D–P Modular Analyzer, Roche Diagnostics GmbH, Mannheim,
Germany).
Ex vivo production of cytokines/chemokines using Whole
Blood Assay (WBA)
To evaluate the role of inflammatory cells in mediating the
cytokine/chemokine responses, the Whole Blood Assay (WBA)
Cytokines, 2009 H1N1, Seasonal Influenza
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peripheral blood mononuclear cells (PBMC) collected from
patients during the course of seasonal influenza infection (similar
studies for pH1N1 infection have been planned). WBA has been
used to study cytokine responses mediated by the inflammatory
cells in patients with other naturally-occurring infections
[16,17,18]. It provides a natural milieu to study cytokine
production, preserving the intercellular interactions and the
circulating stimulatory/inhibitory mediators (including the soluble
receptors), at their physiological concentrations [16]. Briefly,
within 1 hour of EDTA blood collection (kept at room
temperature), blood was diluted 1:1 with RPMI 1640 (Gibco
Laboratories, NY,USA), and 0.5 ml aliquots were deposited in
each well of a 24-well plate (Nalge Nunc International, IL,USA).
The blood culture was then incubated with or without phytohaem-
agglutinin (PHA)(Sigma, MO,USA), at 10 mg/ml; and lipopoly-
saccharide (LPS), at 25 mg/ml (Sigma), for 24 h at 37uCi na5 %
CO2 atmosphere. After incubation, the cell-free supernatant was
harvested and stored at 270uC until CBA for cytokines/
chemokines. PHA is a specific T cell mitogen, and LPS is a B
cell and macrophage mitogen, and a toll-like receptor 4 ligand.
Concentrations of 12 cytokines/chemokines released ex vivo by the
PBMC with or without PHA/LPS stimulation were measured and
reported. The fold-change in increased expression after stimula-
tion (i.e., the ‘responsiveness’) was calculated for each cytokine/
chemokine (post-stimulation concentration4 baseline concentra-
tion)[16].
Statistical analysis
Plasma concentrations of cytokines/chemokines measured at
presentation were described (median and interquartile range,
IQR) and compared between infections caused by different
influenza virus subtypes using the Mann-Whitney U test [15].
Patients with severe pH1N1 pneumonia (defined as radiographic
pneumonia and hypoxemia, with requirement of supplemental
oxygen therapy to maintain oxygen saturation .95%) were also
compared to those with milder illness [7,8]. Correlations between
plasma cytokine/chemokine concentration and clinical variables
were analyzed using the Spearman’s rank correlation coefficient
rho (r)[8,15]. To determine independent factors associated with
intensive care unit (ICU) admission, variables with P-values #0.1
in univariate analyses were entered into logistic regression models;
adjusted odds ratios (OR) and 95% confidence intervals (CI) were
calculated and reported for explanatory variables[8,14,15]. Ex vivo
PBMC cytokine production with or without PHA/LPS stimulation
were compared using the Mann-Whitney U test [16]. The trend
change in cytokine expression by PBMC across the study time
points was analyzed using the Jonckheere-Terpstra test. In all
analyses, a P-value of,0.05 was considered to indicate statistical
significance. All probabilities were 2-tailed. Statistical analysis was
performed using the PASW Statistics software, version 17.0 (SPSS
Inc., Chicago,USA).
Results
Description of study cohorts
Altogether 63 pH1N1 and 53 seasonal influenza (A=45, B=8)
patients were studied. Patients with pH1N1 influenza were
younger (mean6S.D. 42.8619.2 vs 70.5616.7 years; P,0.001),
and less frequently had underlying medical conditions (30% vs
53%; P=0.013). Gender distribution was not different (male, 50%
vs 57%). Both cohorts were hospitalized for severe, compli-
cated influenza diseases: respiratory/cardiovascular complications
71.4% vs 81.1%, p=0.224; oxygen desaturation 55.6% vs 49.1%,
p=0.485; radiographic evidence of pneumonia 57.1% vs 41.5%,
p=0.093. ‘Severe pneumonia’, as defined by radiographic
pneumonia plus hypoxemia, was more common with pH1N1
influenza (54.0% vs 28.3%; P=0.009). The ICU admission rate
was also significantly higher (25.4% vs 1.9%; P,0.001). Two
(3.2%) pH1N1 patients died during the course of hospitalization.
There was no death in the seasonal influenza cohort.
In vivo cytokine/chemokine responses in seasonal and
pandemic H1N1 influenza
Plasma cytokine/chemokine concentrations measured at pre-
sentation for the pH1N1 and seasonal influenza groups are shown
in Table 1. In patients with severe pH1N1 pneumonia, the
proinflammatory cytokine IL-6 was highly elevated [about 15
times above its reference range (up to 54 times) for normal subjects
[8,15]; and 3–4 times higher than the seasonal influenza group,
P,0.05]; there were also increases in CXCL8/IL-8, CCL2/
MCP-1, and sTNFR-1 [about 2–4 times above their normal
reference ranges (up to 8 times)]. Notably, when compared with
the seasonal influenza group, the Th1-related CXCL10/IP-10 and
CXCL9/MIG, and the Th17-related IL-17A were markedly
suppressed in cases of severe pH1N1 pneumonia (2–27 times
lower; P2values ,0.01). Similar results were obtained when only
complicated infections with hypoxemia were compared (Table 1
and footnotes). The measured CXCL9/MIG values were
mostly within the normal reference range, although CXCL10/
IP-10 and IL-17A generally showed some increases. In addition,
IFN-c was less frequently detected in the severe pH1N1
pneumonia group (P,0.001); but a relative increase in IL-10
was observed (P,0.05). In mild pH1N1 infections without
pneumonia, hypercytokinemia was largely absent; most measured
values did not exceed the normal reference ranges.
When compared between different seasonal influenza virus
infections (Table 1), it was found that plasma levels of CXCL9/
MIG, CXCL8/IL-8, sTNFR-1 and CXCL10/IP-10 were higher
in the influenza A/H3N2 subgroup than in the seasonal influenza
A/H1N1 subgroup (by 2–4 times). Greater IL–17A and
interferon-c responses were observed in influenza B than influenza
A patients, but the CXCL9/MIG, CXCL10/IP-10 and sTNFR-1
levels were lower (by 2–30 times).
Serial changes in the plasma cytokine/chemokine concentra-
tions in patients with pH1N1 and seasonal influenza infection
during their first week of hospitalization are described in
Figure 1. There was sustained activation of the proinflammatory
cytokines (IL-6, CXCL8/IL-8, CCL2/MCP-1, sTNFR-1) in
severe pH1N1 pneumonia; the CXCL10/IP-10, CXCL9/MIG
and IL-17A responses remained largely suppressed during the
hospital course. Cytokine activation remained absent with mild
pH1N1 infection. In seasonal influenza, plasma cytokine/chemo-
kine levels (e.g. IL-6, CXCL-8/IL-8, CXCL10/IP-10, CXCL9/
MIG) tended to decline rapidly after hospitalization, especially
among the antiviral-treated patients. Increased CCL5/RANTES
level was noted during the recovery phase of influenza infections.
Sustained hypercytokinemia in pH1N1 influenza was noted to
correspond to a slower viral clearance in the respiratory tract
compared with seasonal influenza: PCR-negativity in nasal/
pharyngeal swabs was found in 55% and 85% on day 3–4, and
67% and 100% on day 6–7 respectively.
There was evidence of collective activation of the pro-
inflammatory cytokines/chemokines in both pH1N1 and seasonal
influenza: plasma IL-6 concentration correlated significantly with
that of CXCL8/IL-8 (Spearman’s rho r+0.623, P,0.001), CCL2/
MCP-1 (r+0.588, P,0.001), and sTNFR-1 (r+0.538, P,0.001).
The Th1-related chemokines CXCL10/IP-10 and CXCL9/MIG
Cytokines, 2009 H1N1, Seasonal Influenza
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Material S1). There was, however, little correlation between IL-6
and CXCL10/IP-10, CXCL9/MIG, or IL–17A levels. C-reactive
protein, serum amyloid A and cortisol levels were all found to be
elevated during influenza infection (Table 1). Plasma C-reactive
protein level significantly correlated with IL-6 (r+0.609, P,0.001)
and sTNFR-1 (r+0.462, P,0.001) levels, but not with other
cytokines/chemokines.
Clinical correlations of the cytokine responses
For pH1N1 influenza, high plasma IL-6 concentration at
presentation (adjusted OR 12.6, 95%CI 2.6–61.5, per log10
unit increase; P=0.002) was independently associated with
ICU admission, adjusted for age, comorbidity and time interval
from onset-to-presentation. Similar associations with ICU
admission were found for CXCL8/IL-8 and CCL2/MCP-1.
Circulating IL-6, CXCL8/IL-8, CCL2/MCP-1, and sTNFR-1
levels were also found to correlate significantly with fever,
tachypnoea, oxygen desaturation and hospital length-of-stay
(Table 2).
For seasonal influenza, significantly higher plasma IL-6,
CXCL8/IL-8, sTNFR-1, CXCL10/IP-10 and C-reactive protein
concentrations were found in patients with respiratory/cardiovas-
cular complications (all P2values,0.05). Plasma cytokine levels,
particularly for IL-6, were found to correlate significantly with
fever, oxygen desaturation and length-of-stay (Table 2). There
were trends to suggest lower plasma IL–17A concentration being
associated with respiratory/cardiovascular complications [media-
n(IQR) 30.0(16.7–50.2) vs 43.4(27.7–62.3) pg/ml], oxygen
desaturation (r+0.231) and longer length-of-stay (r20.229), but
these did not reach statistical significance.
PBMC activation and cytokine/chemokine production in
naturally-occurring influenza
We studied ex vivo cytokine/chemokine production of PBMC in
seasonal influenza infection using WBA (n=53). There were
significant correlations found between ex vivo cytokine production
and the in vivo plasma concentrations measured for IL-6
(Spearman’s rho r+0.329, P=0.017), CCL2/MCP-1 (r+0.568,
P,0.001), CXCL10/IP-10 (r+0.597, P,0.001), CXCL9/MIG
Figure 1. Serial changes in plasma cytokine/chemokine concentrations during the course of hospitalization. There was sustained
elevation of the proinflammatory cytokines (IL-6, CXCL8/IL-8, CCL2/MCP-1, sTNFR-1) in severe pH1N1 pneumonia; the adaptive-immunity related
cytokines (CXCL10/IP-10, CXCL9/MIG, IL-17A) were markedly suppressed compared with seasonal influenza. All patients with pH1N1 influenza (severe
pneumonia, n=34; milder illness, n=29) received antiviral treatment soon after hospitalization/recruitment; none had received high-dose
corticosteroids or other immunosuppressants for ‘viral pneumonitis’ or ‘ARDS’[8]. Among seasonal influenza patients (most had complicated illnesses,
see Table 1 footnotes), 30(57%) received antiviral treatment. Median concentrations at each time point are shown for each group; the interquartile
ranges (presented in Table 1) are omitted here for clarity. Fewer mild pH1N1 and untreated seasonal influenza patients remained hospitalized at day
6–7 for study (Day 1, n=116; Day 3–4, n=62; Day 6–7, n=30).
doi:10.1371/journal.pone.0026050.g001
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In the absence of PHA/LPS stimulation, ex vivo IL-6, CXCL8/IL-
8, CCL2/MCP-1, CXCL10/IP-10 and CXCL9/MIG produc-
tions were found to be highest at baseline, and lowered in the serial
samples obtained during recovery. With PHA/LPS stimulation,
there was greatly increased secretion of these cytokines from the
PBMC; and their ‘responsiveness’ (see Methods) was shown to
restore/increase during the recovery phase (Figure2a and 2b).
To supplement these findings, we report evidence of activation
and enhanced expression of the signaling molecule phospho-p38
mitogen activated protein kinase (MAPK) in the blood mononu-
clear cells during naturally-occurring pH1N1 infection in addition
to seasonal influenza infection; p38 MAPK has been implicated in
the signaling process of the cytokine response in influenza [15].
Details of the results are provided in Supplementary Material
S1.
Discussion
Our study reported different cytokine response patterns in
adults hospitalized for severe pandemic H1N1 and seasonal
influenza. In patients with pH1N1 pneumonia, there was sustained
hyperactivation of the innate, proinflammatory cytokines (e.g. IL-
6, CXCL8/IL-8, CCL2/MCP-1, sTNFR-1), which correlated
with disease severity and outcomes; and in comparison with
seasonal influenza, the adaptive Th1/Th17-immunity related
cytokines (e.g. CXCL10/IP-10, CXCL9/MIG, IL-17A) were
markedly suppressed. These findings suggested that cytokine
dysregulation may play a role in disease pathogenesis.
Our results agree with recent in vitro and in vivo studies
which have shown that an exuberant proinflammatory,
innate cytokine response is the hallmark of severe influenza
disease, in both seasonal and pandemic viruses infections
[8,9,13,19,20,21,22,23,24,25]. IL-6, one of the key proinflamma-
tory cytokines, mediates fever, acute-phase reactions, and in
experimental models shown to induce excessive tissue inflamma-
tion and dysregulate the immune response towards influenza virus
[8,9,13,19,20,25,26,27]. TNF-a (indicated by circulating sTNFR-1)
mediates severe systemic symptoms, and aggravates lung tissue
destruction[13,19,25]. CCL2/MCP-1 and CXCL8/IL-8 have
been shown to recruit and activate monocytes/macrophages
[8,9,19,24,25] and neutrophils [15,19,24] respectively in models
of influenza pneumonia, leading to progression to ARDS. Our
study adds that these cytokines/chemokines correlated significantly
with severity of symptoms including high fever, tachypnoea and
oxygen desaturation, and associated with adverse clinical outcomes
such as ICU admission and longer duration of hospitalization
(Table 2)[8,9,15,19,20,21,26], which indicated their possible
pathogenic roles. However, while in seasonal influenza
these proinflammatory responses are soon downregulated, they
Table 2. Correlations between initial cytokine/chemokine concentrations and clinical parameters at presentation (temperature,
respiratory rate, oxygen saturation) and the clinical outcomes (hospital length-of-stay, ICU admission).
Temperature (6C)
Respiratory Rate
(breaths per min)
Oxygen saturation
(SaO2%)
Length-of-stay
(LOS, days)
Risk of ICU admission
(adjusted OR, 95%CI)
Pandemic H1N1 influenza
IL-6 +0.504** +0.607** 20.391** +0.621** 12.6, 2.6–61.5**
CXCL8/IL-8 +0.480** +0.420** 20.506** +0.528** 17.0, 1.9–151.9**
CCL2/MCP-1 +0.358** +0.442** 20.513** +0.559** 60.9, 3.7–1000.0**
sTNFR-1 +0.368** +0.511** 20.473** +0.424** 1.3, 0.5–3.2
IL-10 +0.447** +0.632** 20.513** +0.548** 23.6, 2.5–226.9**
CXCL10/IP-10 +0.262* –0.155 +0.020 –0.143 1.2, 0.4–3.9
CXCL9/MIG +0.111 –0.154 –0.108 –0.014 1.0, 0.3–3.3
IL-17A +0.135 –0.081 –0.167 –0.059 0.8, 0.2–3.5
CCL5/RANTES –0.072 –0.030 –0.157 0.000 1.1, 0.1–13.3
Seasonal influenza
IL-6 +0.351** -- –0.342* +0.371** --
CXCL8/IL-8 +0.110 -- –0.202 +0.410** --
CCL2/MCP-1 +0.179 -- –0.084 +0.064 --
sTNFR-1 +0.086 -- –0.114 +0.466** --
IL-10 +0.002 -- –0.108 +0.044 --
CXCL10/IP-10 +0.076 -- –0.337* +0.389** --
CXCL9/MIG –0.125 -- –0.182 +0.265 --
IL-17A +0.178 -- +0.231 –0.229 --
CCL5/RANTES +0.059 -- –0.052 –0.231 --
C-reactive protein +0.104 -- –0.411* +0.474** --
For correlations with temperature, respiratory rate, oxygen saturation, and length-of-stay, the Spearman’s rank coefficients (rho) were shown. For risk of ICU admission,
the adjusted odds ratio and the 95% confidence interval (CI) per log10 unit increase in cytokine concentration were shown (adjusted for age, comorbidity and time from
onset). Data on respiratory rate was incomplete in seasonal influenza cases, and there were too few ICU admissions to allow meaningful analysis.
*p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0026050.t002
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[8,21,25,28](Figure 1). We have previously shown that active viral
replication may lead to continuous cytokine activation [8,15]; and it
is likely that the high viral burden and the more prolonged viral
replication in pH1N1 pneumonia have driven a sustained cytokine
response, resulting in progressive tissue inflammation
[2,4,8,9,13,15,21,29]. These findings on the host response do not
contradict with the in vitro studies which have shown that
intrinsically, the pH1N1 virus is a weaker cytokine inducer than
H5N1, but more comparable to the seasonal influenza viruses
[11,12,28,30]. In fact, we observed little difference between the
initial levelsofmost ofthe proinflammatorycytokines (except forIL-
6, see Results) in severe pH1N1 and complicated seasonal infections
[11]; and the adaptive-immunity related cytokines were lower in
pH1N1 (see below). Although sample sizes were small in the
subgroups, we have shown that the cytokine/chemokine responses
in naturally-occurring seasonal influenza caused by different virus
subtypes are generally consistent with those reported in in vitro
studies, and in line with their known symptom severity (influenza
A.B; H3N2.H1N1)[11,22,23,24,30].
Our finding of a strong adaptive-immunity related cytokine
response (e.g. CXCL10/IP-10,CXCL9/MIG, IL–17A; and IFN-c)
in seasonal influenza but a relatively suppressed response in severe
pH1N1 pneumonia is striking. CXCL10/IP-10 and CXCL9/MIG
are stimulated by IFN-c, which together orchestrate the Th1
cellular immune response, known to be important for virus control
in influenza infection [21,31]. IL-17A is a key cytokine involved in
the newly described Th17 adaptive cellular immunity; its role in
host defense against pathogens including influenza virus is
increasingly recognized [9,20,32,33,34,35,36]. Bermejo-Martin JF
et al and To KK et al have reported high levels of proinflammatory
cytokines (e.g. IL-6, CXCL8/IL-8, CCL2/MCP-1) in critically ill
pH1N1 patients; but IL–17A only showed a small increase, and in
fact itwashigherinthe mildercases,correlatingwithenhancedviral
clearance [9,20]. Insignificant rise in IL–17A and IFN-c was
reported by others [19,26]. Although CXCL10/IP-10 generally
showed an increase [9,19,20], our results showed that the response
wasmuchlowerthan that in seasonal influenza.Recent studies have
shown that numerous genes responsible for adaptive-immunity and
T-cell response are downregulated in severe pH1N1 pneumonia
[21,26]; the T-cell functions are impaired, and some subsets
including the Th17 cells are lost [31,32,37]. The impaired adaptive
cellular immunity might have contributed to the delay in viral
clearance in pH1N1 pneumonia, which in turn leads to sustained
activation of the proinflammatory response [8,13,15,20,30,31,38].
Some of the inflammatory/anti-inflammatory cytokines released
(e.g. IL-6, IL-10) might further dysregulate or inhibit the adaptive
immunity, thus forming a vicious cycle [9,13,20,21,27]. Underlying
immunocompromising conditions of the host might worsen these
processes [14,15]. A similar hypothesis has been put forward for
H5N1 disease [11,13,29,39]. Pathogenesis of severe influenza is
complex, involving interactions between different viral (e.g. genetic
constellation, virulence, immune evasion, tropism) and host factors
(e.g. innate and adaptive responses, prior or cross-immunity,
immunosuppression); but our data suggested that cytokine/immune
dysregulation likely plays a role. Further studies are warranted
[11,13,23,24,27,30,38,39].
Ex vivo cytokine production study was performed to investigate
the role of the immune cells in mediating the cytokine response
during seasonal influenza infection. We found significant correla-
tions between the cytokines/chemokines produced by the
mononuclear cells and the plasma assay results, and there were
dynamic changes of cytokine expression and cellular responsive-
ness throughout the course of illness (Figure 2). These findings
suggested that the immune cells are activated, and may be
responsible for part of the cytokine response observed during
naturally-occurring infections. Macrophage/monocyte (in addi-
tion to pneumocytes) have been shown in experimental models as
a key mediator of the proinflammatory responses, and lympho-
cytes (particularly the T-cells) being crucial in the adaptive, cellular
immunity against influenza [13,21,25,30,31,36,37]. Similar studies
on pH1N1 infection have been planned; but available data
suggested that the results might be different (e.g. T-cell anergy to
PHA stimulus), which clearly deserves further investigation
[31,32,37].
Our findings may have important implications. Since the
adaptive, cellular immunity and the associated cytokine responses
are impaired/downregulated in pH1N1 pneumonia, further
immunosuppression (e.g. with high-dose corticosteroid), is unlikely
beneficial and may even be harmful. This is supported by recent
clinical studies which have shown that corticosteroid use may lead
to delayed viral clearance, pneumonia progression, bacterial
superinfection and adverse outcomes in influenza infections
[14,40,41,42]. As such, future research on adjunctive therapy for
severe influenza should consider targeting the proinflammatory
pathways, while preserving immunity for virus control
[13,30,42,43,44,45]. Moreover, a potent and more sustained
antiviral regimen should be considered for viral suppression to
prevent the vicious cycle of inflammatory-cytokine activation in
pH1N1 pneumonia especially among immunocompromised
patients [8,15]. Furthermore, our data suggested that future study
on prognostication of severe influenza infection should consider
the inclusion of cytokine/chemokine variables, because of their
significant correlations with clinical progress and outcomes (e.g. a
10-fold increase in IL-6 is associated with .10 times higher risk for
ICU admission)[8,9,15,20,21,29,31].
The strengths of our study include the comparisons of naturally-
occurring, severe, influenza infections caused by different virus
subtypes; patients were studied under the same clinical settings,
using the same cytokine/chemokine assays. Samples were
collected before antiviral treatment at baseline, and then serially
during the hospital course [14,15]. Corticosteroids for ‘viral
pneumonitis’ and ‘ARDS’, which may confound the cytokine/
chemokine responses was not given in our cohort [7,19,21].
Differences in patient demographic characteristics in pandemic
and seasonal influenza should not affect our interpretation of data,
since the host response patterns and the pathogenesis of severe
forms of influenza disease were studied, which typically occur in
the younger and older individuals respectively (in contrast to the
study of the intrinsic properties of the viruses to induce cytokines).
Further, the suppressed Th1/Th17 cytokine responses in severe
Figure 2. PBMC activation and ex vivo cytokine/chemokine expression during seasonal influenza infection. PBMC actively expressed
IL-6, (CXCL8/IL-8), CCL2/MCP-1, CXCL10/IP-10, and CXCL9/MIG during acute influenza infection; upon illness recovery, cytokine production decreased,
and there was a corresponding increase in cellular responsiveness to stimuli. Cytokine response pre-/post-stimulation and the trend changes in
cytokine expression across time points (with PHA/LPS stimulation – red bars; without stimulation – blue bars; folds increase in expression or the
‘responsiveness’ – gray bars) were compared using the Mann-Whitney U test (asterisks, underlined), and the Jonckheere-Terpstra test (blue/gray
triangles and asterisks), respectively. IL-17A did not appear to be activated via the PHA/LPS stimulation pathway.
doi:10.1371/journal.pone.0026050.g002
Cytokines, 2009 H1N1, Seasonal Influenza
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26050pH1N1 pneumonia could not be easily explained by patient’s
younger age. Ideally, local (lung) production of cytokines should
also be studied; however lower-respiratory secretion/tissue
samples are difficult to obtain, and assay methods have not been
standardized. Given that the lung is a highly vascular organ, it has
been suggested that studying circulating cytokines may still provide
a reasonably good approximation on their response patterns
[15,29]. We studied ex vivo cytokine expression of influenza
patients’ immune cells using WBA and PHA/LPS stimulation,
instead of inactivated viruses that were available. This had avoided
repetitive stimulation with a different virus strain, but we
acknowledge the limitation that not all cytokine signaling pathways
respond to such stimuli (e.g. IL–17A).
In conclusion, we found that in pH1N1 pneumonia the
proinflammatory cytokines were hyperactivated, which correlated
with severe symptoms and adverse outcomes. The adaptive
immunity (Th-1/Th-17)-related cytokine responses were sup-
pressed, in contrast to seasonal influenza. Cytokine/immune
dysregulation likely plays an important role in the pathogenesis of
severe, progressive influenza infection.
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